The tweet was deleted by the author.
But we saved everything 🙂.
OmniAb drew attention this week at the Targeted Radiopharmaceuticals Summit in San Diego, where engagement around Yasmina Abdiche's presentation was notably high.
The company introduced OmniUltra, its in vivo discovery platform focused on structured peptides designed to enable radioligand therapy and other applications. OmniAb outlined the platform's potential for advancing therapeutic development in targeted radiopharmaceuticals. The summit brought together key stakeholders in the industry to explore technological advances and new approaches in the evolving radiopharmaceuticals landscape.
OmniAb previously introduced the OmniUltra platform for in vivo structured peptide discovery at the Targeted Radiopharmaceuticals Summit US 2026 in San Diego. The company highlighted the platform's use in radioligand therapy applications. That presentation set the stage for further discussions on therapeutic innovation at this week's summit.